Barinthus Biotherapeutics (BRNS) Q1 2026 earnings summary

Executive summary

• Focused on developing immunotherapeutic drug candidates for autoimmune and inflammatory diseases, with lead candidate VTP-1000 in Phase 1 for celiac disease and a strategic shift away from infectious disease and oncology programs.

• Entered a merger agreement with Clywedog to form a combined company targeting metabolic and autoimmune diseases, expected to close mid-2026, with significant clinical milestones anticipated in the next 18 months.

• Appointment of Doug Swirsky as CFO effective May 1, 2026, to support strategic and financial operations.

• Net loss for Q1 2026 was $5.5 million, with an accumulated deficit of $309.6 million as of March 31, 2026.

Financial highlights

• Research and development expenses decreased to $3.6 million from $8.3 million year-over-year, reflecting strategic reprioritization and reduced activity in legacy programs.

• General and administrative expenses dropped to $2.5 million from $12.6 million, mainly due to lower personnel costs, depreciation, and foreign exchange gains.

• Cash, cash equivalents, and restricted cash totaled $67.2 million at quarter-end, down from $71.9 million at year-end 2025, mainly due to operating expenses and currency translation losses.

• Net loss attributable to shareholders was $5.5 million ($0.14 per share) for Q1 2026, compared to $19.6 million ($0.49 per share) in Q1 2025.

• Net cash used in operating activities was $3.4 million, a significant improvement from $14.9 million in the prior year period.

Outlook and guidance

• Existing cash resources are expected to fund operations for at least the next 12 months; combined company’s cash runway projected to extend through 2027, supported by existing and new investors.

• Continued net operating losses are anticipated as clinical development progresses; additional funding may be required if the merger is not consummated.

• Research and development expenses for legacy assets expected to continue decreasing, while investment in autoimmune programs may remain steady or increase.

• Merger with Clywedog expected to close mid-2026, with the combined entity to be renamed and listed under a new ticker.